Efficacy of Roflumilast in the Treatment of Psoriasis
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Roflumilast (Daxas®), a selective, long-acting inhibitor of the enzyme phosphodiesterase-4
(PDE4), is used for severe chronic obstructive pulmonary disease. Recent research suggest
roflumilast is effective in treating psoriasis. The aim of this investigator-initiated trial
is to study the efficacy of oral roflumilast in patients with plaque psoriasis. This has not
previously been done.